Compare BHVN & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHVN | IOVA |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 881.3M |
| IPO Year | 2017 | N/A |
| Metric | BHVN | IOVA |
|---|---|---|
| Price | $10.76 | $2.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 12 |
| Target Price | ★ $30.36 | $10.45 |
| AVG Volume (30 Days) | 2.9M | ★ 12.7M |
| Earning Date | 03-02-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $250,425,000.00 |
| Revenue This Year | N/A | $60.71 |
| Revenue Next Year | N/A | $59.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 175.62 |
| 52 Week Low | $7.48 | $1.64 |
| 52 Week High | $44.28 | $6.16 |
| Indicator | BHVN | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 47.81 |
| Support Level | $10.61 | $2.25 |
| Resistance Level | $12.90 | $2.77 |
| Average True Range (ATR) | 0.80 | 0.22 |
| MACD | -0.23 | -0.03 |
| Stochastic Oscillator | 17.66 | 31.01 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.